Author

R. T. Lawlor

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:cancer & tumor microenvironment· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 3 Approach:statistical model· 3 Research Focus:differential expression· 2

Frequent Co-Authors

A. Scarpa· 6 shared E. Fiorini· 4 shared F. Lupo· 4 shared V. Corbo· 4 shared D. Pasini· 3 shared J. T. Siveke· 3 shared L. Veghini· 3 shared M. Bevere· 3 shared

Activity by Year

2019-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

A. Scarpa

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in Pancreatic Ductal Adenocarcinoma

R. Blazquez-Encinas, E. Alors-Perez, M. T. Moreno-Montilla, V. Garcia-Vioque, M. E. Sanchez-Frias, A. Mafficini, J. L. Lopez-Canovas, C. Bousquet, M. D. Gahete, R. T. Lawlor, R. M. Luque, A. Scarpa, A. Arjona-Sanchez, S. Pedraza-Arevalo, A. Ibanez-Costa, J. P. Castano

This study identifies EIF4A3 as an oncogenic factor in PDAC by showing its overexpression correlates with poor prognosis and its role in regulating RNA splicing and tumor growth.

bioRxiv · Dec 7, 2023Cancer Biology

Differential Activity of MAPK signalling Defines Fibroblast Subtypes in Pancreatic Cancer

L. Veghini, D. Pasini, P. Delfino, V. Corbo, E. Fiorini, F. Lupo, M. Bevere, C. Luchini, R. T. Lawlor, A. Scarpa, P. F.-Y. Cheung, J. T. Siveke, C. Vicentini, D. Filippini, S. L. D'Agosto, , R. Fang

This study identifies MAPK signalling as defining fibroblast subtypes in pancreatic cancer, linking MAPKhigh CAFs to poor prognosis and immune evasion.

bioRxiv · Oct 30, 2023Cancer Biology

ecDNA amplification of MYC drives intratumor copy-number heterogeneity and adaptation to stress in PDAC

A. Malinova, D. Schreyer, E. Fiorini, D. Pasini, M. Bevere, S. D'Agosto, S. Andreani, F. Lupo, L. Veghini, S. Grimaldi, S. Pedron, C. Nourse, R. Salvia, G. Malleo, A. Ruzzenente, , V. Corbo

bioRxiv · Sep 27, 2023Cancer Biology

The axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC

F. Lupo, F. Pezzini, E. Fiorini, A. Adamo, L. Veghini, M. Bevere, C. Frusteri, P. Delfino, S. D'Agosto, S. Andreani, G. Piro, A. Malinova, F. De Sanctis, D. Pasini, R. T. Lawlor, , V. Corbo

This study shows SEMA3A promotes aggressive basal-like PDAC by enhancing metastasis and modulating the tumor microenvironment through macrophage polarization and T cell exclusion.

bioRxiv · Feb 25, 2023Cancer Biology

Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer

L. K. Godfrey, J. Forster, S.-T. Liffers, C. Schroeder, J. Koester, L. Henschel, K. U. Ludwig, M. Trajkovic-Arsic, D. Behrens, A. Scarpa, R. T. Lawlor, K. E. Witzke, B. Sitek, S. A. Johnsen, S. Rahmann, , J. T. Siveke

This study identifies adaptive DNA methylation changes and clonal expansion as mechanisms of resistance to MEKi in PDAC, showing reversibility upon drug withdrawal.

bioRxiv · May 20, 2022 · PreprintCancer Biology

MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages

P. Delfino, C. Neander, D. Filippini, S. D'Agosto, C. Vicentini, E. Fiorini, F. Lupo, C. Fiorini, B. Rusev, G. Temgue Tane, F. De Sanctis, M. Simbolo, S. Ugel, V. Bronte, M. Fassan, , V. Corbo

This study shows that MEK inhibition in mouse pancreatic cancer reduces anti-inflammatory macrophages and enhances gemcitabine efficacy by altering the tumor microenvironment.

bioRxiv · Sep 8, 2019 · PreprintCancer Biology